Breaking Down China Life Insurance Company Limited Financial Health: Key Insights for Investors

Investors scanning China Life Insurance Company Limited's financials will find a mix of robust growth and manageable risks: first-half 2025 revenue surged to RMB 173.65 billion, up 49.66% year‑over‑year, with trailing‑12‑month revenue at RMB 371.67 billion (+24.97% YoY) after a 2024 annual revenue of RMB 314.44 billion (+43.33%), while record gross written premiums reached RMB 608.2 billion (+5.1%) and value of new business rose 25.1%, supporting improved margins as investment returns recovered; profitability shows a net profit of RMB 40.9 billion in H1 2025 (+7% YoY), net margin up to 9.69% from 9.10%, investment income jumping 152% (gross) with net profit from investments +174% YoY, ROE at 28.42% and ROIC at 15.56% alongside an EPS (TTM) of 4.25 and a P/E of 4.95 that imply compelling valuation metrics complemented by a conservative balance sheet-total investments of RMB 6,999.4 billion, debt/equity of 0.37, current ratio 7.90, debt/EBITDA 1.14, interest coverage 47.99, total debt HK$36.97 billion versus cash HK$120.93 billion, core solvency 154.58% and comprehensive solvency 211.64%, cash equivalents RMB 113.39 billion and assets exceeding RMB 7 trillion-while valuation multiples remain attractive (P/B 0.77, P/S 1.29, EV/EBITDA 6.43, forward P/E 7.29) and analysts target HK$23.55, yet material risks persist (contractual service margin down 31% YoY, Q2 bottom line retreating 31% YoY, exposure to market volatility and regulatory shifts) even as the company pursues digitalization, asset‑liability optimization and new product expansion to capture future growth; read on for the detailed breakdown and what these numbers mean for your investment view

China Life Insurance Company Limited (2628.HK) - Revenue Analysis

China Life delivered notable top-line expansion across 2024-2025, driven by stronger investment returns, asset allocation optimization and improved value creation in new business. Key metrics show accelerated growth in both short-term and trailing periods, and record premium inflows that underpin future earnings potential.

• 1H 2025 total revenue: RMB 173.65 billion (up 49.66% vs 1H 2024)
• TTM ending Sep 30, 2025 total revenue: RMB 371.67 billion (up 24.97% YoY)
• 2024 full-year revenue: RMB 314.44 billion (up 43.33% vs 2023)
• Gross written premiums (latest reported): RMB 608.2 billion (up 5.1% YoY)
• Value of new business: +25.1% vs restated 2023

Drivers and implications for investors:

• Investment performance: Recovery in equity markets boosted investment income, a key contributor to the large YoY revenue jumps in 2024 and 1H 2025.
• Asset allocation: Tactical rebalancing toward higher-yielding assets improved overall returns and supported TTM revenue growth of 24.97%.
• Premium momentum: RMB 608.2 billion in gross written premiums (+5.1% YoY) supplies future fee and investment income streams.
• New business quality: 25.1% increase in value of new business suggests potential for margin expansion and enhanced long-term profitability.

For related investor-focused context and shareholder composition, see: Exploring China Life Insurance Company Limited Investor Profile: Who's Buying and Why?

China Life Insurance Company Limited (2628.HK) - Profitability Metrics

• Net profit (H1 2025): RMB 40.9 billion - +7% YoY
• Net profit margin: 9.69% (up from 9.10% YoY)
• Gross investment income: +152% YoY
• Net profit contribution from investments: +174% YoY
• Return on equity (ROE): 28.42%
• Return on invested capital (ROIC): 15.56%
• EPS (trailing 12 months): RMB 4.25
• Price-to-earnings (P/E): 4.95x

• Investment performance is the primary swing factor: the 152% jump in gross investment income and the 174% rise in investment-linked net profit materially lifted margins and ROE.
• Strong ROE (28.42%) paired with ROIC (15.56%) indicates both equity and operational capital are generating robust returns.
• Valuation perspective: EPS of RMB 4.25 and a P/E of 4.95x suggest the market is pricing the stock at a low multiple given current earnings power.

China Life Insurance Company Limited (2628.HK) Debt vs. Equity Structure

• Leverage: debt-to-equity of 0.37 indicates capital structure tilted toward equity - lower financial risk and capacity for additional strategic borrowing if needed.
• Liquidity: current ratio of 7.90 and HK$120.93 billion cash versus HK$36.97 billion debt provide a multi-turn cash buffer for short-term obligations and policyholder liabilities.
• Coverage: interest coverage near 48x and debt-to-EBITDA of 1.14 show earnings comfortably cover financing costs and debt servicing.

• Valuation context: EV/EBITDA of 6.43 positions the company at a moderate multiple versus the sector - reflecting stable earnings and significant investment assets (RMB 6,999.4 billion).
• Balance-sheet flexibility: net cash position (cash > debt) supports capital returns, reinvestment in the investment book, or selective bolt-on M&A without overleveraging.

China Life Insurance Company Limited (2628.HK) - Liquidity and Solvency

• Core solvency ratio: 154.58% - provides a buffer over statutory minima and indicates the company's core capital relative to insurance risk exposure.
• Comprehensive solvency ratio: 211.64% - reflects total available capital including adjustments, signaling strong overall capital adequacy.
• Cash and cash equivalents (as of 30 Jun 2025): RMB 113.39 billion - supports immediate liquidity needs and short-term claims payments.
• Total assets: > RMB 7 trillion - large asset base supports long-term liabilities and investment diversification.
• Debt-to-equity ratio: 0.37 - low financial leverage, reducing bankruptcy risk and interest burden sensitivity.
• Current ratio: 7.90 - indicates strong short-term solvency and working-capital sufficiency.

• Large cash buffer (RMB 113.39bn) combined with high current ratio reduces refinancing and immediate liquidity risk.
• High comprehensive solvency (211.64%) provides capacity to absorb market shocks and underwriting volatility.
• Low debt-to-equity (0.37) keeps interest-rate exposure and credit risk limited on the balance sheet.

China Life Insurance Company Limited (2628.HK) - Valuation Analysis

• P/E (trailing): 4.95 - deep earnings yield relative to many global insurers.
• P/B: 0.77 - trading below stated book value, implying market discounts to reported net assets.
• P/S: 1.29 - reasonable relative to top-line; reflects lower valuation pressure versus peers with higher growth.
• EV/EBITDA: 6.43 - suggests an enterprise-level valuation that could be attractive to value-focused acquirers.
• Forward P/E: 7.29 - indicates analysts see earnings growth/moderation rather than steep deterioration.
• Consensus price target: HK$23.55 - analysts' median target implying upside from the prevailing market price.

• Implication for investors: low absolute multiples (P/E, P/B) point to potential value opportunity but require due diligence on capital adequacy, reserve quality, and embedded investment risks.
• EV/EBITDA and forward P/E indicate the market prices in operational stability rather than robust near-term growth.
• Gap between book value and market price highlights sensitivity to solvency perceptions and regulatory/accounting treatments of insurance liabilities.

China Life Insurance Company Limited (2628.HK) - Risk Factors

China Life faces multiple interrelated risks that can materially affect earnings, reserve dynamics and capital metrics. Key drivers include interest rate movements, market volatility, competitive pressure and operational/regulatory headwinds.

• Declining interest rates - directly compress new-business profitability and increase insurance service expenses.
• Market volatility - investment returns and surplus capital are sensitive to equity and fixed-income swings.
• Competitive intensity - pricing and product design pressure margins across life and health segments.
• Regulatory change - solvency, reserve and product rules could require capital or product adjustments.
• Operational complexity - managing a large distribution force and sustaining service quality can raise costs and execution risk.

Recent company-reported dynamics illustrate these risks in numbers:

Operational and strategic risk items to monitor:

• Product mix: heavy guaranteed-rate products amplify sensitivity to falling yields and increase future policyholder participation costs.
• Investment allocation: equity and alternative exposures can boost returns but raise short-term volatility and capital strain under stress scenarios.
• Distribution costs and productivity: rising salesforce costs or lower persistency reduce long-term margins.
• Regulatory tightening: changes in solvency or reserve calibrations can force capital raising or constrain new business.

For context on the company's broader profile, see China Life Insurance Company Limited: History, Ownership, Mission, How It Works & Makes Money

China Life Insurance Company Limited (2628.HK) - Growth Opportunities

• Market position and scale: China Life holds a leading share of China's life-insurance market - roughly in the high-teens to low-20s percent range by direct premium income - providing a strong platform for cross-sale, geographic expansion, and product distribution leverage.
• Digitalization and intelligent services: management has accelerated investment in digital channels, AI-driven underwriting and claims, and mobile client engagement, targeting improved cost-to-serve and faster conversion. Reported digital customer interactions and online sales have grown materially year-over-year (digital policies and servicing increasing approximately 20-40% in recent reporting periods).
• Value creation & profitability improvement: the company is prioritizing margin-enhancing product mixes (protection and fee-based savings products), expense discipline and pricing optimization to lift embedded value and return on equity (ROE). Target ROE improvement is communicated as a multi-year objective, aiming to move into a higher-single-digit to low-double-digit range vs. historical levels.
• Strategic investments & national development: China Life is expanding into strategic sectors aligned with national priorities (healthcare, elderly care services, pension solutions) via both internal product development and selective investments/joint ventures to monetize long-term demographic trends.
• Asset-liability management (ALM): in a prolonged low-rate environment the company has enhanced ALM practices - lengthening duration, optimizing credit allocation, and increasing alternative asset exposure - to protect spread income and the value of long-term liabilities.
• Business diversification: management is rolling out new product lines (linked products, bancassurance / agency upgrades, wealth management and pension products) and exploring adjacent financial services to reduce reliance on traditional long-duration guaranteed products.

• Operational levers: improving persistency, adjusting product mix toward protection and fee-based products, reducing acquisition expense via digital channels, and targeted bancassurance partnerships.
• Investment levers: shift into higher-yielding credit, infrastructure, and selectively into equities/private markets while preserving duration matching for long-term liabilities.
• New-business experiments: pension solutions, health-linked products, connected elderly-care services, and wealth-management wrappers aimed at recurring fee income.